Update in new anabolic therapies for osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 4, 2010, Pages 1496-1504

  Canalis, Ernesto ^a,b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; ANABOLIC AGENT; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; DICKKOPF 1 PROTEIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PARATHYROID HORMONE; PROTEASOME INHIBITOR; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 1; WNT PROTEIN; SOMATOMEDIN C;

BINDING AFFINITY; BONE MASS; BONE REMODELING; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; HUMAN; MESENCHYME CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKELETON; TARGET ORGAN; AGED; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MALE; MIDDLE AGED; PHYSIOLOGY;

AGED; ANABOLIC AGENTS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOPOROSIS; PARATHYROID HORMONE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77951624097     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2677     Document Type: Review

References (77)

1. Looker AC, Orwoll ES, Johnston Jr CC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP 1997 Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761-1768
2. Recker R, Lappe J, Davies KM, Heaney R 2004 Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19: 1628-1633 (Pubitemid 41094325)
3. Parfitt AM 2001 The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res 16:1583-1585
4. Canalis E 2005 The fate of circulating osteoblasts. N Engl J Med 352:2014-2016
5. Canalis E 2007 Skeletal growth factors. In: Marcus R, Feldman D, Nelson D, Rosen C, eds. Osteoporosis, 3rd ed. San Diego: Academic Press; 529-546
6. Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235 (Pubitemid 36515285)
7. Krishnan V, Bryant HU, Macdougald OA 2006 Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202-1209
8. Gazzerro E, Canalis E 2006 Skeletal actions of insulin-like growth factors. Expert Rev Endocrinol Metab 1:47-56
9. Gazzerro E, Canalis E 2006 Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7:51-65 (Pubitemid 46044349)
10. Kawano Y, Kypta R 2003 Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-2634 (Pubitemid 36857216)
11. Kisselev AF, Goldberg AL 2001 Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758
12. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR 2003 Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782
13. Westendorf JJ, Kahler RA, Schroeder TM 2004 Wnt signaling in osteoblasts and bone diseases. Gene 341:19-39
14. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, McMahon AP, Long F 2007 Noncanonical Wnt signaling through G protein-linked PKCδ activation promotes bone formation. Dev Cell 12:113-127 (Pubitemid 46002598)
15. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S 2005 Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342-41351
16. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y 2003 Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3- independent β-catenin degradation. J Cell Biol 162:899-908 (Pubitemid 37087729)
17. Glass 2nd DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G 2005 Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764
18. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280: 21162-21168
19. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837
20. Smith E, Frenkel B 2005 Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and -independent manner. J Biol Chem 280:2388-2394
21. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
22. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA 2005 Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280:2498-2502
23. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942
24. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158 (Pubitemid 40962421)
25. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583 (Pubitemid 41446595)
26. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS 2004 The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18:1222-1237 (Pubitemid 38591287)
27. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869
28. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc- Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G 2006 Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934-945
29. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM 2001 Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84-88 (Pubitemid 32044524)
30. Miyazono K 1999 Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 25:91-93 (Pubitemid 29322068)
31. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y 2000 Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27:479-486
32. Centrella M, McCarthy TL, Canalis E 1991 Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol Cell Biol 11:250-258 (Pubitemid 21895202)
33. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143:74-83 (Pubitemid 34056405)
34. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML 2008 Asoluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105:7082-7087
35. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, Canalis E 2003 Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144: 1972-1978 (Pubitemid 36543336)
36. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E 2005 Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146:655-665 (Pubitemid 40129821)
37. Gazzerro E, Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Economides AN, Canalis E 2007 Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem 282:31549-31557
38. Zhang Y, Zhang Q 2009 Bone morphogenetic protein-7 and gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 383:1-3
39. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
40. Canalis E, Centrella M, Burch W, McCarthy TL 1989 Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 83:60-65
41. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S 2001 Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349-4356 (Pubitemid 32907063)
42. Sims NA, Clément-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA 2000 Bone homeostasis in growth hormone receptor- null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106:1095-1103
43. Adams TE, Epa VC, Garrett TP, Ward CW 2000 Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093 (Pubitemid 30598754)
44. Grey A, Chen Q, Xu X, Callon K, Cornish J 2003 Parallel phosphatidylinositol- 3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 144:4886-4893 (Pubitemid 37378403)
45. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA 2002 Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 277:38239-38244
46. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL 2000 Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674-2682
47. Mochizuki H, Hakeda Y, Wakatsuki N, Usui N, Akashi S, Sato T, Tanaka K, Kumegawa M 1992 Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 131:1075-1080
48. Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD 2006 Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350-1358 (Pubitemid 44300041)
49. Yakar S, Canalis E, Sun H, Mejia W, Kawashima Y, Nasser P, Courtland HW, Williams V, Bouxsein M, Rosen C, Jepsen KJ 2009 Serum IGF-1 determines skeletal strength by regulating sub-periosteal expansion and trait interactions. J Bone Miner Res 24:1481-1492
50. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL 2002 Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012
51. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, Ohta T, Kadowaki T, Nakamura K, Kawaguchi H 2000 Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105:935-943
52. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543
53. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935 (Pubitemid 40994212)
54. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
55. Grisanti M, Niu QT, Fan W, Asuncion F, Lee J, Steavenson S, Chen Q, Li J, Geng Z, Kostenuik P, Lacey DL, Simonet WS, Ominsky MS, Li X, Richards WG 2006 Dkk-1 inhibition increases bone mineral density in rodents. J Bone Miner Res 21(Suppl 1):S25 (Abstract)
56. Bodine PV, Stauffer B, Ponce-de-Leon H, Bhat RA, Mangine A, Seestaller-Wehr LM, Moran RA, Billiard J, Fukayama S, Komm BS, Pitts K, Krishnamurthy G, Gopalsamy A, Shi M, Kern JC, Commons TJ, Woodworth RP, Wilson MA, Welmaker GS, Trybulski EJ, Moore WJ 2009 A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44:1063-1068
57. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E 2006 Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/β-catenin but not bone morphogenetic protein signaling. J Biol Chem 281:6203-6210 (Pubitemid 43847550)
58. Vestergaard P 2008 Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics. Curr Drug Saf 3:185-189
59. Giles RH, van Es JH, Clevers H 2003 Caught up in a Wntstorm:Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24
60. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM 2009 Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837-851
61. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR 2008 Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833-2842
62. Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE, Ucran JA, Pearsall AE, Khanzode D, Kumar R, Underwood KW, Roberts B, Seehra J, Bouxsein ML 2010 Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46:64-71
63. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML 2009 Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24: 744-752
64. Giustina A, Mazziotti G, Canalis E 2008 Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559
65. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP 1998 Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 83:42574262
66. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A 1996 Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864-3870 (Pubitemid 26380388)
67. Misra M, Klibanski A 2006 Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord 7:91-99
68. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A 2002 Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87:2883-2891 (Pubitemid 34655358)
69. LeRoith D, Baserga R, Helman L, Roberts Jr CT 1995 Insulin-like growth factors and cancer. Ann Intern Med 122:54-59
70. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A 2006 Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 21:520-528
71. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R 1995 Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 10:1844-1852
72. Doga M, Bonadonna S, Gola M, Solerte SB, Amato G, Carella C, Giustina A 2005 Current guidelines for adult GH replacement. Rev Endocr Metab Disord 6:63-70
73. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14: 690-709 (Pubitemid 24016657)
74. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446
75. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J 2000 Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595-1604
76. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF 2003 Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575
77. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR 2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirtysix- month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346-3355